Last reviewed · How we verify

NCT03092973

Carotid Intima Media Thickness (CIMT) in Epistaxis

Completed Last updated 30 October 2017
What this trial tests

trial testing Ultrasound in Epistaxis in 82 participants. Completed in 30 June 2017.

Timeline
1 December 2016
Primary endpoint
30 June 2017
30 June 2017

Quick facts

Lead sponsorUniversity of Zurich
StatusCompleted
Study typeOBSERVATIONAL
Enrollment82
Start date1 December 2016
Primary completion30 June 2017
Estimated completion30 June 2017
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Epistaxis or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Epistaxis is a very frequent emergency among adults and often needs specialised treatment in an ENT-department. Among others, atherosclerosis is often named as a reason for an increased risk for Epistaxis. To evaluate whether or not this is the case, the investigators examined the carotid intima media thickness via ultrasound in patients who were treated in the ENT-department of the University Hospital of Zurich.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Association of epistaxis with atherosclerotic cardiovascular disease.
    Kunz SM, Holzmann D, Soyka MB. · · 2019 · cited 8× · PMID 30549051 · DOI 10.1002/lary.27604

Verify or expand the search:

Other trials of Ultrasound

Trials testing the same drug.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing